Clinical Report: Surgical Outcomes in Hemorrhagic Brain Metastases

Overview

This study retrospectively analyzed surgical outcomes in patients with hemorrhagic brain metastases (BM) from various primary tumors. It assessed the risk of perioperative hemorrhagic complications and the safety of surgical tumor removal, focusing on differences related to tumor origin and coagulation status.

Background

Brain metastases are the most common intracerebral malignancies in adults, frequently arising from lung, breast, colorectal cancers, melanoma, and renal cell carcinoma. Advances in imaging and systemic cancer management have increased BM detection rates. Certain tumor types, such as melanoma and renal carcinoma, are associated with higher risks of intracerebral hemorrhage (ICH), complicating surgical management. Despite improvements in neurosurgical techniques, data on outcomes after resection of hemorrhagic BM remain limited.

Data Highlights

The study included consecutive patients undergoing complete surgical resection of histologically confirmed BM between 2016 and 2017. Pre- and postoperative coagulation parameters (aPTT, PT, INR, platelet count, hemoglobin, hematocrit) were monitored and corrected as needed. Anticoagulation medications were paused according to protocol prior to surgery. Clinical performance was assessed by Karnofsky Performance Status (KPS), prognosis by Recursive Partitioning Analysis (RPA) and disease-specific Graded Prognostic Assessment (dsGPA), and comorbidities by Charlson Comorbidity Index (CCI). Imaging was used to evaluate tumor volume, hemorrhage presence, and extracranial disease burden.

Key Findings

• Surgical resection of hemorrhagic BM is feasible and can be performed safely with appropriate perioperative management.
• Patients with BM from melanoma, renal cell carcinoma, and hepatocellular carcinoma have a higher predisposition to tumor-associated intracerebral hemorrhage.
• Strict perioperative coagulation monitoring and management, including pausing anticoagulants and correcting coagulation parameters, are critical to minimize hemorrhagic complications.
• Complete tumor resection was achieved in all included patients, with exclusion of those with incomplete resections or hemorrhage from non-tumor causes.
• Clinical performance and prognosis scores (KPS, RPA, dsGPA) alongside comorbidity indices (CCI) provide valuable stratification for surgical candidacy and expected outcomes.

Clinical Implications

Clinicians should consider the primary tumor origin when evaluating hemorrhagic risk in BM patients undergoing surgery. Careful preoperative coagulation assessment and management protocols are essential to reduce perioperative bleeding complications. Multidisciplinary decision-making involving neurosurgery and oncology teams optimizes patient selection and timing for surgical intervention.

Conclusion

Surgical removal of hemorrhagic brain metastases is a safe and effective treatment option when performed with rigorous perioperative coagulation management. Tumor origin influences hemorrhagic risk, underscoring the need for tailored surgical planning.

References

1. Author/Source/Year -- Factors Influencing Surgical Outcomes in Hemorrhagic Brain Metastases